Acción PMGM PRIVETERRA ACQUISITION CORP. II
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas Priveterra Acquisition Corp. II

Acciones

PMGM

US8765451047

Tiempo real estimado Cboe BZX
Otros sitios de cotización
 15:30:05 08/05/2024 		Varia. Cinco días. Varia. 1 de enero.
11,14 USD +0,45 % Gráfico intradía de Priveterra Acquisition Corp. II -1,07 % +0,91 %
2023 Priveterra Acquisition Corp. II informa de los resultados del tercer trimestre y de los nueve meses finalizados el 30 de septiembre de 2023 CI
2023 Priveterra Acquisition Corp. II informa de los resultados del segundo trimestre y de los seis meses finalizados el 30 de junio de 2023 CI

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
Priveterra Acquisition Corp. II Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K
AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine
AEON Biopharma Announces Redemption of Public Warrants - March 29, 2024
CORRECTION -- AEON Biopharma Announces Redemption of Public Warrants
AEON Biopharma Announces Redemption of Public Warrants
AEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results
AEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine
AEON Biopharma Announces $15 Million Financing Transaction and Termination of Forward Purchase Agreements
AEON Biopharma Presents Positive Clinical and Pre-clinical Data for ABP-450 (prabotulinumtoxinA) in Treating Cervical Dystonia and PTSD, Respectively, at a Leading Neurotoxin Conference
AEON Biopharma Completes Enrollment in Phase 2 Study of ABP-450 (prabotulinumtoxinA) for Preventive Treatment of Chronic Migraine
Priveterra Acquisition Corp. II Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
AEON Biopharma Reports Third Quarter 2023 Financial Results
AEON Biopharma Announces Topline Results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Episodic Migraine
AEON Biopharma Presents Positive Results from Phase 2 Clinical Trial of ABP-450 (prabotulinumtoxinA) in Cervical Dystonia at the International Parkinson and Movement Disorders Society Congress®
AEON Biopharma Receives Notice of Allowance from USPTO for a Patent Covering Use of Botulinum Toxins to Treat Migraine Headache
Priveterra Acquisition Corp. II Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Tastemaker Acquisition Corp. has Changed its Name to Priveterra Acquisition Corp. II
Tastemaker Acquisition Corp. Announces the Resignation of Christopher Bradley as Chief Financial Officer
Tastemaker Acquisition Corp. Announces Board Changes
Tastemaker Acquisition Corp. Announces CEO Changes
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción PMGM
  4. Noticias Priveterra Acquisition Corp. II
  5. Otros idiomas